All sponsors

Ultragenyx Pharmaceutical Inc $RARE

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-37
RECRUITING2
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO75%

Delay Index: of 8 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +19.0 months). See all sponsors →

Open Ultragenyx Pharmaceutical Inc on the live radar map → 📅 $RARE readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Orbit
NCT05125809
P2/3Active, not recruitingOsteogenesis Imperfecta1832025-10-20 (+8 mo)
Cosmic
NCT05768854
P3Active, not recruitingOsteogenesis Imperfecta692025-10-23 (-1 mo)
setrusumab
NCT06636071
P3Active, not recruitingOsteogenesis Imperfecta62027-01
Triheptanoin
NCT05933200
P3Active, not recruitingLong-chain Fatty Acid Oxidation Disorders (LC-FAOD)692027-08 (+11 mo)
No Investigational Product
NCT04360265
P3Enrolling by invitationMucopolysaccharidosis IIIA; MPS IIIA412027-08 (+19 mo)
DTX301
NCT05345171
P3Active, not recruitingOTC Deficiency372027-09 (+33 mo)
UX016
NCT07511556
P1/2RecruitingGNE Myopathy242028-12
UX701
NCT04884815
P1/2Active, not recruitingWilson Disease822029-03 (+27 mo)
UX111
NCT02716246
P2/3RecruitingMPS IIIA; Sanfilippo Syndrome362029-03 (+111 mo)